Skip to main content
. Author manuscript; available in PMC: 2017 Jul 21.
Published in final edited form as: Lancet Oncol. 2016 Jun 6;17(7):994–1003. doi: 10.1016/S1470-2045(16)30125-5

Figure 2. Change from baseline in HRQoL scores on FKSI-DRS.

Figure 2

Note: Only time points where data were available for five or more patients are shown. Between arms, from week 4 (p<0·001) through week 76 (p=0·043), a mean difference was observed between nivolumab and everolimus. Within nivolumab, an improvement from baseline starting at week 20 (0·6 [3·8], p=0·031) through week 104 (3·5 [4·1], p=0·001); within everolimus, a deterioration from baseline starting at week 4 (–1·5 [4·5], p<0·001) through week 32 (–1·1 [4·7], p=0·019) and again from week 60 (–1·6 [4·4], p=0·016) through week 64 (–1·5 [4·8], p=0·040). FKSI-DRS=Functional Assessment of Cancer Therapy–Kidney Symptom Index–Disease Related Symptoms. HRQoL=health-related quality of life.